Zacks Small Cap Has Pessimistic Outlook of MIRA Q4 Earnings

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) – Equities research analysts at Zacks Small Cap cut their Q4 2024 earnings per share estimates for shares of MIRA Pharmaceuticals in a research note issued on Thursday, December 19th. Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings per share of ($0.29) for the quarter, down from their prior forecast of ($0.19). The consensus estimate for MIRA Pharmaceuticals’ current full-year earnings is ($0.60) per share. Zacks Small Cap also issued estimates for MIRA Pharmaceuticals’ FY2026 earnings at ($0.54) EPS.

MIRA Pharmaceuticals (NASDAQ:MIRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.04.

A number of other research analysts have also weighed in on the company. Rodman & Renshaw began coverage on MIRA Pharmaceuticals in a report on Monday, September 30th. They issued a “buy” rating and a $17.00 price objective on the stock. RODMAN&RENSHAW upgraded shares of MIRA Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th.

MIRA Pharmaceuticals Stock Up 6.0 %

MIRA opened at $1.06 on Monday. The company has a market cap of $17.55 million, a PE ratio of -1.89 and a beta of 1.93. MIRA Pharmaceuticals has a twelve month low of $0.51 and a twelve month high of $5.01. The company has a 50-day moving average price of $1.36 and a 200 day moving average price of $1.37.

Insider Activity

In other news, CEO Erez Aminov sold 55,410 shares of MIRA Pharmaceuticals stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $1.39, for a total transaction of $77,019.90. Following the transaction, the chief executive officer now owns 1,105,790 shares in the company, valued at $1,537,048.10. The trade was a 4.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 6.65% of the company’s stock.

Institutional Investors Weigh In On MIRA Pharmaceuticals

A hedge fund recently raised its stake in MIRA Pharmaceuticals stock. Suncoast Equity Management raised its position in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) by 125.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 90,000 shares of the company’s stock after purchasing an additional 50,000 shares during the quarter. Suncoast Equity Management owned about 0.61% of MIRA Pharmaceuticals worth $117,000 as of its most recent SEC filing. 35.16% of the stock is currently owned by institutional investors and hedge funds.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.